[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1110172T1 - Φαρμακευτικες συνθεσεις περιλαμβανουσες ανταγωνιστες ταχυκινινων και εναν αναστολεα επαναπροσληψεως σεροτονινης - Google Patents

Φαρμακευτικες συνθεσεις περιλαμβανουσες ανταγωνιστες ταχυκινινων και εναν αναστολεα επαναπροσληψεως σεροτονινης

Info

Publication number
CY1110172T1
CY1110172T1 CY20081101376T CY081101376T CY1110172T1 CY 1110172 T1 CY1110172 T1 CY 1110172T1 CY 20081101376 T CY20081101376 T CY 20081101376T CY 081101376 T CY081101376 T CY 081101376T CY 1110172 T1 CY1110172 T1 CY 1110172T1
Authority
CY
Cyprus
Prior art keywords
tahacinin
reposal
serotonine
inclusive
inhibitor
Prior art date
Application number
CY20081101376T
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1110172T1 publication Critical patent/CY1110172T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Σύνθεση περιλαμβάνουσα μία ένωση τύπου (Ι)
CY20081101376T 1999-10-07 2008-11-27 Φαρμακευτικες συνθεσεις περιλαμβανουσες ανταγωνιστες ταχυκινινων και εναν αναστολεα επαναπροσληψεως σεροτονινης CY1110172T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923748.9A GB9923748D0 (en) 1999-10-07 1999-10-07 Chemical compounds
EP04076650A EP1454901B1 (en) 1999-10-07 2000-10-05 Pharmaceutical compositions comprising tachykinins antagonists and a serotonin reuptake inhibitor.

Publications (1)

Publication Number Publication Date
CY1110172T1 true CY1110172T1 (el) 2015-01-14

Family

ID=10862304

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20081101376T CY1110172T1 (el) 1999-10-07 2008-11-27 Φαρμακευτικες συνθεσεις περιλαμβανουσες ανταγωνιστες ταχυκινινων και εναν αναστολεα επαναπροσληψεως σεροτονινης
CY20091100969T CY1110104T1 (el) 1999-10-07 2009-09-18 Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20091100969T CY1110104T1 (el) 1999-10-07 2009-09-18 Παραγωγα της πιπεραζινης ως αναστολεις ταχυκινινων

Country Status (33)

Country Link
US (6) US6951861B1 (el)
EP (3) EP1454901B1 (el)
JP (1) JP4776844B2 (el)
KR (2) KR100817373B1 (el)
CN (1) CN100413850C (el)
AR (2) AR025975A1 (el)
AT (3) ATE435215T1 (el)
AU (1) AU768780B2 (el)
BR (1) BR0014541A (el)
CA (1) CA2386515C (el)
CO (1) CO5251467A1 (el)
CY (2) CY1110172T1 (el)
CZ (1) CZ302340B6 (el)
DE (3) DE60012031T2 (el)
DK (3) DK1218359T3 (el)
ES (3) ES2222927T3 (el)
GB (1) GB9923748D0 (el)
HK (3) HK1052506B (el)
HU (1) HUP0203136A3 (el)
IL (2) IL148964A0 (el)
MX (1) MXPA02003515A (el)
MY (1) MY130907A (el)
NO (1) NO323776B1 (el)
NZ (2) NZ518144A (el)
PE (1) PE20010741A1 (el)
PL (1) PL201191B1 (el)
PT (3) PT1460066E (el)
SI (3) SI1460066T1 (el)
TN (1) TNSN00194A1 (el)
TR (1) TR200200936T2 (el)
TW (1) TWI225485B (el)
WO (1) WO2001025219A2 (el)
ZA (1) ZA200202589B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327600T3 (es) * 1999-02-18 2009-11-02 Novasearch Ag Uso de antagonistas del receptor de la 5-ht3 para el tratamiento de enfermedades musculoesqueleticas.
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0108595D0 (en) 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
GB0108594D0 (en) * 2001-04-05 2001-05-23 Glaxo Group Ltd Chemical compounds
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
GB0119797D0 (en) 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
DE10209145A1 (de) * 2002-03-01 2003-09-04 Bayer Cropscience Ag Halogenbenzole
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
JP4079727B2 (ja) * 2002-09-06 2008-04-23 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体とその製造方法
JP2006516581A (ja) * 2003-01-27 2006-07-06 グラクソ　グループ　リミテッド 機能性消化不良を治療するための化学化合物の使用
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
BRPI0410630A (pt) * 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
US20060148781A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder in a non-human mammal
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
US20050113365A1 (en) * 2003-11-10 2005-05-26 Sir Isaac Newton Enterprises Llc Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome
US20060148783A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
US20070142367A1 (en) * 2003-11-10 2007-06-21 Lundeen James E Method and medicine for treating gastrointestinal disorder including fecal incontinence
CA2547467A1 (en) * 2003-11-28 2005-06-09 Tanabe Seiyaku Co., Ltd. Piperidine compound and method for producing same
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
JP4904945B2 (ja) 2006-06-30 2012-03-28 セントラル硝子株式会社 光学活性１−（フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル）アルキルアミンｎ−モノアルキル誘導体の製造方法
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5510040B2 (ja) * 2010-04-28 2014-06-04 セントラル硝子株式会社 光学活性（ｒ）−１−（４−フルオロフェニル）エチルアミンを得る光学分割
WO2012175434A1 (en) 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
WO2013124286A1 (en) * 2012-02-22 2013-08-29 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds
WO2015024203A1 (en) * 2013-08-20 2015-02-26 Leo Pharma A/S Novel neurokinin 1 receptor antagonist compounds ii
WO2016102967A1 (en) 2014-12-23 2016-06-30 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
US10399949B2 (en) 2015-12-07 2019-09-03 Kissei Pharmaceutical Co., Ltd. NK1 receptor antagonist
BR112019021125A2 (pt) 2017-04-10 2020-05-12 Chase Therapeutics Corporation Combinação de antagonista de nk1 e método para tratamento de sinucleinopatias
EA202090180A1 (ru) 2017-06-30 2020-05-26 Чейс Терапьютикс Корпорейшн Композиции nk1-антагониста и способы лечения депрессии
SG11202002706XA (en) 2017-10-05 2020-04-29 Biogen Inc Process for preparing alpha-carboxamide pyrolidine derivatives

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4219554A (en) 1974-05-09 1980-08-26 Toyama Chemical Company, Limited Novel penicillins and cephalosporins and process for producing same
US4379152A (en) 1974-05-09 1983-04-05 Toyama Chemical Co., Ltd. Cephalosporins
US4110327A (en) 1974-05-09 1978-08-29 Toyama Chemical Co., Ltd. 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives
US4410522A (en) 1974-05-09 1983-10-18 Toyama Chemical Co., Ltd. Cephalosporins
US4112090A (en) 1974-05-09 1978-09-05 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4087424A (en) 1974-05-09 1978-05-02 Toyama Chemical Co., Ltd. Novel penicillins and cephalosporins and process for producing the same
US4327097A (en) 1974-05-09 1982-04-27 Toyama Chemical Co., Ltd. Novel penicillins
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
JPS57118587A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel penicillin
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
GB8709666D0 (en) 1987-04-23 1987-05-28 Beecham Group Plc Compounds
GB8713061D0 (en) 1987-06-04 1987-07-08 Beecham Group Plc Compounds
US5109014A (en) 1990-12-10 1992-04-28 Jacobson Richard M N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides
SE9100860D0 (sv) 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
EP0916346A3 (en) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5348955A (en) 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
AU3085895A (en) 1994-07-26 1996-02-22 Sankyo Company Limited N-phenylated amide and urea derivatives
DE19520499C2 (de) 1994-09-17 2003-06-18 Boehringer Ingelheim Kg Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung
US5696123A (en) 1994-09-17 1997-12-09 Boehringer Ingelheim Kg Neurokinin antagonists
US5998444A (en) 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
US5576317A (en) 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5700801A (en) 1994-12-23 1997-12-23 Karl Thomae, Gmbh Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
CZ189197A3 (cs) 1994-12-23 1998-01-14 Dr. Karl Thomae Gmbh Piperazinové deriváty, způsob výroby a farmaceutický prostředek s jejich obsahem
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
DE19608665A1 (de) 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6057323A (en) 1996-03-08 2000-05-02 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000507576A (ja) 1996-04-03 2000-06-20 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質トランスフェラーゼ阻害剤
CA2249559A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036593A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU3359697A (en) 1996-07-08 1998-02-02 Yamanouchi Pharmaceutical Co., Ltd. Bone resorption inhibitors
CA2260269A1 (en) * 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
US5929077A (en) 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
EP0942730A1 (en) 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating bipolar disorders
US6114315A (en) 1996-12-02 2000-09-05 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
US5977104A (en) 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
AU741725B2 (en) 1997-08-27 2001-12-06 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU751950B2 (en) 1997-11-24 2002-09-05 Merck & Co., Inc. Substituted beta-alanine derivatives as cell adhesion inhibitors
CN1152877C (zh) * 1998-12-14 2004-06-09 藤泽药品工业株式会社 哌嗪衍生物
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
CZ20021166A3 (cs) 2002-11-13
AU768780B2 (en) 2004-01-08
WO2001025219A3 (en) 2001-12-13
JP4776844B2 (ja) 2011-09-21
TWI225485B (en) 2004-12-21
PT1460066E (pt) 2009-09-10
US20060122192A1 (en) 2006-06-08
DK1218359T3 (da) 2004-10-18
SI1218359T1 (en) 2005-02-28
JP2003511377A (ja) 2003-03-25
US20080249108A1 (en) 2008-10-09
NO20021637L (no) 2002-06-06
IL148964A0 (en) 2002-11-10
DE60012031D1 (de) 2004-08-12
KR20070112308A (ko) 2007-11-22
HUP0203136A2 (hu) 2003-02-28
DK1454901T3 (da) 2009-01-12
KR100817373B1 (ko) 2008-03-27
EP1218359A2 (en) 2002-07-03
NO323776B1 (no) 2007-07-02
SI1460066T1 (sl) 2009-12-31
TR200200936T2 (tr) 2002-07-22
SI1454901T1 (sl) 2009-02-28
EP1460066A1 (en) 2004-09-22
NZ531127A (en) 2005-11-25
IL148964A (en) 2007-02-11
PT1218359E (pt) 2004-10-29
PL356261A1 (en) 2004-06-28
ATE407125T1 (de) 2008-09-15
CA2386515A1 (en) 2001-04-12
US20030028021A1 (en) 2003-02-06
US7071196B2 (en) 2006-07-04
WO2001025219A2 (en) 2001-04-12
US6951861B1 (en) 2005-10-04
US20040209893A1 (en) 2004-10-21
ES2329130T3 (es) 2009-11-23
MY130907A (en) 2007-07-31
EP1218359B1 (en) 2004-07-07
CN1391564A (zh) 2003-01-15
KR100857671B1 (ko) 2008-09-08
CO5251467A1 (es) 2003-02-28
DE60040176D1 (de) 2008-10-16
CY1110104T1 (el) 2015-01-14
HK1065798A1 (en) 2005-03-04
TNSN00194A1 (en) 2005-11-10
EP1454901A1 (en) 2004-09-08
US7345041B2 (en) 2008-03-18
HUP0203136A3 (en) 2003-03-28
CZ302340B6 (cs) 2011-03-23
PE20010741A1 (es) 2001-07-18
KR20020038800A (ko) 2002-05-23
DE60012031T2 (de) 2005-07-07
NZ518144A (en) 2004-04-30
US7625904B2 (en) 2009-12-01
US20040048862A1 (en) 2004-03-11
AU7913900A (en) 2001-05-10
EP1454901B1 (en) 2008-09-03
MXPA02003515A (es) 2002-09-02
PT1454901E (pt) 2008-12-12
ZA200202589B (en) 2003-08-27
BR0014541A (pt) 2002-09-17
ATE270664T1 (de) 2004-07-15
CN100413850C (zh) 2008-08-27
AR077414A2 (es) 2011-08-24
DK1460066T3 (da) 2009-11-02
AR025975A1 (es) 2002-12-26
CA2386515C (en) 2011-06-07
US6642240B2 (en) 2003-11-04
HK1052506A1 (en) 2003-09-19
ES2312917T3 (es) 2009-03-01
PL201191B1 (pl) 2009-03-31
ATE435215T1 (de) 2009-07-15
GB9923748D0 (en) 1999-12-08
DE60042501D1 (de) 2009-08-13
HK1052506B (zh) 2008-12-19
NO20021637D0 (no) 2002-04-05
HK1066537A1 (en) 2005-03-24
ES2222927T3 (es) 2005-02-16
EP1460066B1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
CY1110172T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανουσες ανταγωνιστες ταχυκινινων και εναν αναστολεα επαναπροσληψεως σεροτονινης
TW200510368A (en) Pharmaceutical compositions and combinations of novel non-imidazole compounds
CY1105575T1 (el) Ενωσεις αμιδιου και χρηση αυτων
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
DK1140918T3 (da) Thrombininhibitorer
CY1106534T1 (el) Αρωματικες εξαμελεις κυκλικες ενωσεις που περιεχουν αζωτο
CY1106425T1 (el) Ενωσις βενζυλαμινης και φαρμακευτικη χρησις αυτης
DK1479385T3 (da) Anvendelse af cyclooxygenase-2 inhibitorer til behandling og forebyggelse af neoplasi
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
NO974495D0 (no) Forbindelse og sammensetninger for levering av aktive midler
CY1105912T1 (el) Αναστολεις συγκολλησης κυτταρου
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
PA8548001A1 (es) Derivados aromaticos de acidos dicarboxilicos
CY1105385T1 (el) Παραγωγα αλφα-αμινο-οξεων, μεθοδος για την παρασκευη αυτων και χρηση αυτων σαν αναστολεις διπεπτιδυλ-πεπτιδασης iv (dpp iv)
IL160769A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
SE0000540D0 (sv) New compounds
FI934274A0 (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
NO20016232D0 (no) Amorfe salpetersyre-estere og farmasöytiske preparater inneholdene disse
HK1049832A1 (zh) 雪花胺的新衍生物和類似物
ATE235462T1 (de) Metalloproteinase-inhibitoren
NO923265D0 (no) Benzol(f)quinolinoner
GR1000460B (el) Μεθοδος παρασκευης παραγωγων καψαικινης.
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
CY1106201T1 (el) Αναλογα δισκοδepμολιδης και η φαρμακευτικη τους χρηση